On 23 December 2013, the agreement was signed to create the Institut d’Investigació Sanitària Illes Balears (IdISBa) –formerly the IdISPA– between the Health Department of the Balearic Islands, the Balearic Health Service (IBSalut), which encompasses Son Espases University Hospital, Son Llàtzer Hospital and the Mallorca Primary Healthcare Service, the University of the Balearic Islands (UIB) through the University Institute of Health Sciences Research (IUNICS) and the Balearic Islands Blood and Tissue Bank Foundation.
The IdISBa was created from the most pioneering groups of our participating institutions, which were assessed in relation to four key sections: scientific production, R&D&I projects and results, income per activity, and training and teaching. In so doing, a Scientific Plan was devised with researchers meeting the required criteria of excellence..
As the scientific director of the IdISBa I am aware of certain major challenges. The first of these is to ensure that research groups, which include a total of more than 550 professional involved in research activity, have a base from which to interact and carry out joint and multidisciplinary projects. To that end, research groups have been divided into seven common thematic areas that constitute our main lines of research.
These projects and common lines of research need to be in line with the recommendations for national and international research policies. We will also be strengthening translational research and policies relating to technological innovation and transfer, because any investment into research that does not produce a return on that investment now has to be called into question.
To consolidate the Institute we need to secure operating and upkeep funds which must by necessity be efficient and competitive within the current framework. Cutbacks in research policies and funding are dramatic, with many young researchers unable to develop their careers in research. We hope that polices change, and the best way to do that must be by showing that we can attract talent, create wealth and results for society, and be able to compete and adapt in this global environment.
We have significant strengths to achieve this: a sufficient critical mass of researchers, new facilities that are both spacious and well equipped in terms of technology, coverage of the entire value chain of research (basic groups and both primary and tertiary clinical groups) and the enthusiasm of working together in a new Institute.
If we work together and are organised, the results will soon be seen.
Dr. Miquel Fiol Sala